美股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

三倍做多标普生物-Direxion

231.99

-11.1000-4.57%

盘后：231.21-0.7800-0.34%19:59 EDT

成交量：29.56万

成交额：7,010.13万

市值：6.20亿

市盈率：- -

高：244.67

开：241.52

低：230.22

收：243.09

52周最高：341.93

52周最低：102.35

股本：267.45万

流通股本：267.45万

量比：0.45

换手率：11.05%

股息：0.90

股息率：0.39%

净资产收益率：--

总资产收益率：--

市净率：--

市盈率(LYR):- -

数据加载中...

总览公司新闻资讯公告

TPG考虑以50亿美元出售医疗保健软件公司Lyric

TPG探索出售医疗保健软件公司Lyric

医疗板块市场综述：多空观点交锋

医疗保健板块动态：市场快讯汇总

医疗保健板块动态：市场快讯综述

医疗保健板块快讯：市场动态一览

摩根士丹利：Grindr医疗健康业务蕴藏巨大商机

医疗保健板块动态汇总：市场快讯

Tenet Healthcare（THC）拟私募发行15亿美元票据，置换到期债务

大家人寿9.8亿元投资接力基金后者投向硬科技、医疗健康等领域

泰达生物(08189)与星辰通用签署战略合作框架协议共同推动医疗健康具身智能技术体系、产品体系和解决方案的形成与产业化落地

英国药品和医疗保健产品监管局已受理Biosplice公司关于洛雷西文特治疗膝骨关节炎的申请，并正式启动评估程序。

医疗保健板块市场快讯汇总

医疗保健板块动态：市场快讯汇总

医疗保健板块市场快讯汇总

2070元/月，佛山这笔钱上调

医疗健康板块动态：市场快讯汇总

人保健康保险大连分公司被罚27万，涉聘任不合格人员等

阿斯利康(AZN.US)乳腺癌新药获FDA加速批准，华尔街预计2032年销售额有望冲刺23亿美元

阿斯利康(AZN.US)乳腺癌新药获FDA加速批准，华尔街预计2032年销售额有望冲刺23亿美元

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/hans/stock/LABU/news?page=8"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"LABU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LABU\",,,,,undefined,":{"symbol":"LABU","market":"US","secType":"STK","nameCN":"三倍做多标普生物-Direxion","latestPrice":231.99,"timestamp":1791835200000,"preClose":243.09,"halted":0,"volume":295561,"hourTrading":{"tag":"盘后","latestPrice":231.21,"preClose":231.99,"latestTime":"19:59 EDT","volume":3834,"amount":888365.3656,"timestamp":1791849594803,"change":-0.78,"changeRate":-0.003362,"amplitude":0.007343},"delay":0,"changeRate":-0.04566210045662098,"floatShares":2674486,"shares":2674486,"eps":0,"marketStatus":"已收盘","change":-11.1,"latestTime":"10-12 16:00:00 EDT","open":241.52,"high":244.6716,"low":230.2215,"amount":70101341.22782,"amplitude":0.059443,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":3,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1791878400000},"marketStatusCode":5,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":243.09,"sharesOutstanding":3074486,"nav":242.822,"aum":649423578.22,"dividendRate":0.003877,"bidAskSpread":0.002692,"preHourTrading":{"tag":"盘前","latestPrice":242.43,"preClose":243.09,"latestTime":"09:29 EDT","volume":24862,"amount":6085203.2304,"timestamp":1791811795117,"change":-0.66,"changeRate":-0.002715,"amplitude":0.021844},"postHourTrading":{"tag":"盘后","latestPrice":231.21,"preClose":231.99,"latestTime":"19:59 EDT","volume":3834,"amount":888365.3656,"timestamp":1791849594803,"change":-0.78,"changeRate":-0.003362,"amplitude":0.007343},"volumeRatio":0.453297,"impliedVol":0.9772,"impliedVolPercentile":0.7331},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LABU\",,,,,undefined,":{"symbol":"LABU","floatShares":2674486,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.453297,"shares":2674486,"dividePrice":0.8994,"high":244.6716,"amplitude":0.059443,"preClose":243.09,"low":230.2215,"week52Low":102.3547,"pbRate":"--","week52High":341.93,"institutionHeld":0,"latestPrice":231.99,"eps":0,"divideRate":0.003877,"volume":295561,"delay":0,"ttmEps":0,"open":241.52,"prevYearClose":159.39,"prevWeekClose":243.09,"prevMonthClose":265.79,"prevQuarterClose":265.79,"fiveDayClose":257.38,"twentyDayClose":268.39,"sixtyDayClose":265.56},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LABU\",params:#limit:5,,,undefined,":[{"date":"2025-09-23","symbol":"LABU","amount":0.10273,"announcedDate":"2025-09-22","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-23","defaultRemindTime":1758634200000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-30","payableDate":"2025-09-23","currency":"USD","dateTimestamp":1758600000000,"payDate":"2025-09-30"},{"date":"2025-06-24","symbol":"LABU","amount":0.21897,"announcedDate":"2025-06-23","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-24","defaultRemindTime":1750771800000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-07-01","payableDate":"2025-06-24","currency":"USD","dateTimestamp":1750737600000,"payDate":"2025-07-01"},{"date":"2025-03-25","symbol":"LABU","amount":0.10714,"announcedDate":"2025-03-24","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-25","defaultRemindTime":1742909400000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-01","payableDate":"2025-03-25","currency":"USD","dateTimestamp":1742875200000,"payDate":"2025-04-01"},{"date":"2024-06-25","symbol":"LABU","amount":0.15021,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-06-25","defaultRemindTime":1719322200000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-07-02","payableDate":"2024-06-25","currency":"USD","dateTimestamp":1719288000000,"payDate":"2024-07-02"},{"date":"2024-03-19","symbol":"LABU","amount":0.16064,"announcedDate":"2024-03-18","type":"dividend","market":"US","newRecordDate":"2024-03-20","defaultRemindTime":1710855000000,"name":"三倍做多标普生物-Direxion","recordDate":"2024-03-26","payableDate":"2024-03-20","currency":"USD","dateTimestamp":1710820800000,"payDate":"2024-03-26"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LABU\",market:\"US\",,,undefined,":[{"executeDate":"2018-06-19","recordDate":"2018-06-20","paymentDate":"2018-06-26","value":0.01932,"currency":"USD"},{"executeDate":"2018-09-25","recordDate":"2018-09-26","paymentDate":"2018-10-02","value":0.0954,"currency":"USD"},{"executeDate":"2018-12-27","recordDate":"2018-12-28","paymentDate":"2019-01-04","value":0.09621,"currency":"USD"},{"executeDate":"2019-03-19","recordDate":"2019-03-20","paymentDate":"2019-03-26","value":0.10973,"currency":"USD"},{"executeDate":"2019-06-25","recordDate":"2019-06-26","paymentDate":"2019-07-02","value":0.03745,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LABU\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LABU\",pageSize:20,pageCount:8,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2666955978","title":"TPG考虑以50亿美元出售医疗保健软件公司Lyric","url":"https://stock-news.laohu8.com/highlight/detail?id=2666955978","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666955978?lang=zh_cn&edition=fundamental","pubTime":"2026-09-10 09:48","pubTimestamp":1789004922,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["IGM","BK4550","BK4581","BK4588","NOBL","XLV","CGVV","XBI","BK4585","VHT","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666553284","title":"TPG探索出售医疗保健软件公司Lyric","url":"https://stock-news.laohu8.com/highlight/detail?id=2666553284","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666553284?lang=zh_cn&edition=fundamental","pubTime":"2026-09-10 07:38","pubTimestamp":1788997084,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4588","CGVV","BK4585","VHT","XBI","NOBL","BK4581","IGM","XLV","LABU","BK4550"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123618563","title":"医疗板块市场综述：多空观点交锋","url":"https://stock-news.laohu8.com/highlight/detail?id=1123618563","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1123618563?lang=zh_cn&edition=fundamental","pubTime":"2026-09-10 04:53","pubTimestamp":1788987194,"startTime":"0","endTime":"0","summary":"最新一期医疗板块市场快讯已发布，涵盖多家制药巨头的最新动态与分析师观点。本轮快讯于美国东部时间4:20、12:20和16:50在道琼斯通讯社独家刊出。**1107 ET**——加拿大皇家银行资本市场分析师在研报中指出，近期临床试验受挫意味着诺华制药必须在剩余管线产品的市场推广上做到近乎完美，抑或寻求并购交易。RBC给予该股\"与板块持平\"评级，目标价定为120瑞士法郎。诺华股价微跌0.3%，报111.44法郎。协和麒麟周二表示，该研究未能达到主要终点。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XLV","BK4585","BK4581","XBI","BK4588","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191167112","title":"医疗保健板块动态：市场快讯汇总","url":"https://stock-news.laohu8.com/highlight/detail?id=1191167112","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1191167112?lang=zh_cn&edition=fundamental","pubTime":"2026-09-10 00:37","pubTimestamp":1788971848,"startTime":"0","endTime":"0","summary":"1107 GMT - 加拿大皇家银行资本市场分析师在研究报告中指出，近期临床试验受挫意味着诺华必须近乎完美地将其余管线产品推向市场，或寻求交易合作，但这家瑞士制药商不应操之过急。\"他们补充称，心血管药物pelacarsen和神经肌肉药物del-desiran的失败提高了诺华管线的门槛，因为这两款药物本是抵消即将到来的专利到期所造成销售损失的重要候选产品。RBC首次覆盖该股，给予\"与行业一致\"评级，目标价定为120瑞士法郎。该股下跌0.3%，报111.44法郎。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4581","LABU","BK4588","XLV","BK4585","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104370787","title":"医疗保健板块动态：市场快讯综述","url":"https://stock-news.laohu8.com/highlight/detail?id=1104370787","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1104370787?lang=zh_cn&edition=fundamental","pubTime":"2026-09-09 16:22","pubTimestamp":1788942151,"startTime":"0","endTime":"0","summary":"涵盖医疗保健板块的最新市场快讯，于美国东部时间4:20、12:20及16:50在道琼斯通讯社独家发布。该分析师表示，del-desiran原本是近期120亿美元收购Avidity的首个有力佐证。股价下挫4.7%，报2,251.0日元。2239 GMT——Petra Capital表示，由于美国食品药品监督管理局未对Echo IQ用于检测心力衰竭的工具EchoSolv HF给予批准，该公司股价今日可能遭遇抛售。FDA出具了“非实质性等同”判定。业界不乏企业在解决相关问题后最终获得FDA批准的案例。该机构将该股评级从“持有”下调至“卖出”。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XLV","BK4588","LABU","BK4581","BK4585","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196486882","title":"医疗保健板块快讯：市场动态一览","url":"https://stock-news.laohu8.com/highlight/detail?id=1196486882","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1196486882?lang=zh_cn&edition=fundamental","pubTime":"2026-09-09 04:57","pubTimestamp":1788901078,"startTime":"0","endTime":"0","summary":"聚焦医疗保健领域的最新市场快讯。本专栏内容仅通过道琼斯通讯社在美东时间4:20、12:20及16:50准时发布。受此消息影响，该公司股价应声下挫10%。这家美资投行认为，市场共识似乎低估了产品组合持续优化对利润率带来的积极影响。随着肾病药物Voyxact等自有资产逐渐接棒合作产品，成为这家日本制药企业的主要收入驱动力，Jefferies预测，在这一转型过程中，公司的利润增速将超越收入增速。为此，Jefferies将大冢的目标股价从12,700日元上调至14,000日元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XBI","BK4585","BK4581","XLV","LABU","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183339770","title":"摩根士丹利：Grindr医疗健康业务蕴藏巨大商机","url":"https://stock-news.laohu8.com/highlight/detail?id=1183339770","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1183339770?lang=zh_cn&edition=fundamental","pubTime":"2026-09-09 02:42","pubTimestamp":1788892936,"startTime":"0","endTime":"0","summary":"美东时间14:40——Grindr或将演变为一家披着约会应用外衣的医疗健康企业。该公司已借旗下Woodwork业务涉足远程医疗领域，该业务主要提供勃起功能障碍等病症的治疗药物。然而，摩根士丹利分析师在与Grindr管理层会晤后发布的研报中指出，Grindr的\"医疗健康雄心远不止于Woodwork\"。管理层认为，未来的健康相关收入机遇有望超越其核心业务规模。该公司正积极布局性传播疾病的预防与管理领域，并着眼于长远，旨在为平台用户提供全方位的临床医疗服务。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IAI","LU1064131342.USD","LU1720051108.HKD","LU0210528500.USD","BK4127","LU1668664300.SGD","LU2111349929.HKD","LU0528227936.USD","LU0320765646.SGD","XBI","LU0267386448.USD","LU0882574139.USD","LU1363072403.SGD","BK4534","LU0314104364.USD","LU0971096721.USD","LU1732799900.SGD","LU1791710400.SGD","LU1989772923.USD","KBWB","LU2089284900.SGD","LU2347655156.SGD","BK4588","LU2357305700.SGD","HCSG","IE00BKVL7J92.USD","LU0128526141.USD","LU2487616109.SGD","BK4581","LU1988902786.USD","LU2089283258.USD","LABU","BK4585","LU0557290698.USD","BK4077","LU0390134368.USD","LU1720051017.SGD","LU1732800096.USD","LU1162221912.USD","IE00B775SV38.USD","BK4504","SOCL","LU0912757837.SGD","LU1074936037.SGD","LU0158827948.USD","LU2028103732.USD","LU0106261372.USD","XLV","LU2271345857.HKD","BK4137","LU2133065610.SGD","LU1244550577.SGD","LU0234570918.USD","BK4516","LU1244550221.USD","LU0225283273.USD","LU0795875169.SGD","LU0006306889.USD","LU2023251221.USD","LU2264538146.SGD","IE00BZ1G4Q59.USD","LU1244550494.USD","LU0106831901.USD","LU0158827781.USD","LU0098860793.USD","LU0795875086.SGD","IE00B3S45H60.SGD","GRND","LU1548497426.USD","LU1989772840.SGD","LU1791710582.SGD","LU0029874061.USD","MS","LU0053666078.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112978991","title":"医疗保健板块动态汇总：市场快讯","url":"https://stock-news.laohu8.com/highlight/detail?id=1112978991","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1112978991?lang=zh_cn&edition=fundamental","pubTime":"2026-09-09 00:23","pubTimestamp":1788884589,"startTime":"0","endTime":"0","summary":"最新一期医疗保健板块市场快讯，涵盖行业动向与个股表现，于美国东部时间4:20、12:20及16:50通过道琼斯通讯社独家发布。该公司股价应声下跌10%。杰富瑞称，肾病药物Voyxact及其他自有资产正逐步取代合作产品，成为这家日本制药企业的主要收入驱动力。随着这一转型持续推进，该行预计利润增速将快于收入增速。杰富瑞将大冢目标价从12,700日元上调至14,000日元。该公司股价小幅上涨0.3%，报11,770日元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABU","XBI","XLV","BK4588","BK4581","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665753923","title":"Tenet Healthcare（THC）拟私募发行15亿美元票据，置换到期债务","url":"https://stock-news.laohu8.com/highlight/detail?id=2665753923","media":"金吾财讯","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665753923?lang=zh_cn&edition=fundamental","pubTime":"2026-09-08 21:15","pubTimestamp":1788873326,"startTime":"0","endTime":"0","summary":"金吾财讯 | Tenet Healthcare（THC）周二公布债务操作计划，拟通过私募方式发行15亿美元、2034年到期的全新优先票据，用于对同等规模存量债务实施再融资。本次发行所得净资金，搭配公司现有现金，将全额赎回2027年11月到期，票面利率5.125%的优先有担保第一留置权票据。新票据属于无担保优先债务，和公司当前以及未来的其他无担保优先债务享有同等清偿顺位。本次票据发行还需要完成定价流程，并满足各类常规交割条件。票据仅依据相关证券豁免规则，面向合格机构投资者进行发售。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250107/MDE2NGUxYWJlMGQ4OGQwMTU5ZTY5YzEzNTY0MzU1Mzgx.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/MDE2NGUxYWJlMGQ4OGQwMTU5ZTY5YzEzNTY0MzU1Mzgx.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"305820","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4581","LU0963586101.USD","BK4585","LU1201861165.SGD","THC","LU2324357040.USD","XBI","LU0130103400.USD","XLV","BK4185","LU0648000940.SGD","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665273123","title":"大家人寿9.8亿元投资接力基金 后者投向硬科技、医疗健康等领域","url":"https://stock-news.laohu8.com/highlight/detail?id=2665273123","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665273123?lang=zh_cn&edition=fundamental","pubTime":"2026-09-08 19:25","pubTimestamp":1788866725,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["XBI","BK4585","IXJ","BK4581","BK4550","XLV","LABU","BK4588","VHT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665324454","title":"泰达生物(08189)与星辰通用签署战略合作框架协议 共同推动医疗健康具身智能技术体系、产品体系和解决方案的形成与产业化落地","url":"https://stock-news.laohu8.com/highlight/detail?id=2665324454","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665324454?lang=zh_cn&edition=fundamental","pubTime":"2026-09-08 18:40","pubTimestamp":1788864000,"startTime":"0","endTime":"0","summary":"智通财经APP讯，泰达生物 公布，公司与湖南星辰通用机器人有限公司已签署战略合作框架协议。双方将本着平等自愿、优势互补、场景牵引、联合创新、资源共享、长期合作的原则，围绕医疗健康大模型与具身智能技术的深度融合，共同推动医疗健康具身智能技术体系、产品体系和解决方案的形成与产业化落地。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1493464.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","BK4550","VHT","XBI","BK4588","WDRN","08189","XLV","BK1113","159760","IXJ","BK4581","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665654324","title":"英国药品和医疗保健产品监管局已受理Biosplice公司关于洛雷西文特治疗膝骨关节炎的申请，并正式启动评估程序。","url":"https://stock-news.laohu8.com/highlight/detail?id=2665654324","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665654324?lang=zh_cn&edition=fundamental","pubTime":"2026-09-08 18:33","pubTimestamp":1788863626,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["CGVV","NOBL","BK4585","XBI","BK4588","VHT","LABU","XLV","BK4581","BK4550"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169238098","title":"医疗保健板块市场快讯汇总","url":"https://stock-news.laohu8.com/highlight/detail?id=1169238098","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1169238098?lang=zh_cn&edition=fundamental","pubTime":"2026-09-08 16:25","pubTimestamp":1788855909,"startTime":"0","endTime":"0","summary":"不过，分析师注意到，公司对2030年后实现中个位数百分比增长的雄心未作任何表态。杰富瑞认为，即便近期一款多发性硬化症口服新药取得了成功，但若缺少del-desiran和del-brax这两款自Avidity Biosciences收购而来的药物，要确立市场对公司2030年代增长前景的信心仍面临重重挑战。该公司股价下挫10%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4581","BK4585","BK4588","LABU","XBI","XLV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166930636","title":"医疗保健板块动态：市场快讯汇总","url":"https://stock-news.laohu8.com/highlight/detail?id=1166930636","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1166930636?lang=zh_cn&edition=fundamental","pubTime":"2026-09-08 04:52","pubTimestamp":1788814379,"startTime":"0","endTime":"0","summary":"1035 ET - 杰富瑞分析师指出，阿斯利康凭借其新药Ectamah正在开辟乳腺癌治疗的全新范式，该药刚刚获得美国食品药品监督管理局的上市许可。分析师们认为，这无疑是近年来乳腺癌领域最具分量的批准之一。尽管Ectamah的获批具有重大临床意义，但杰富瑞也提醒，目前其适用人群仅为全体乳腺癌患者中的一部分，这在短期内限制了其商业价值。该公司股价小幅上扬0.5%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","XBI","BK4588","XLV","LABU","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124637396","title":"医疗保健板块市场快讯汇总","url":"https://stock-news.laohu8.com/highlight/detail?id=1124637396","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1124637396?lang=zh_cn&edition=fundamental","pubTime":"2026-09-08 00:22","pubTimestamp":1788798177,"startTime":"0","endTime":"0","summary":"1035 GMT——杰富瑞分析师指出，阿斯利康凭借其新药Ectamah，正在开启乳腺癌治疗的全新范式，该药物刚刚获得美国食品药品监督管理局的批准。分析师评价，这堪称近年来乳腺癌领域最具分量的审批之一。不过杰富瑞也提醒，尽管Ectamah获批在临床上意义重大，但目前其适用人群仅为全体乳腺癌患者中的特定亚群，这在一定程度上限制了其商业价值。该公司股价上涨0.5%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XBI","BK4581","BK4585","BK4588","LABU","XLV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665315217","title":"2070元/月，佛山这笔钱上调","url":"https://stock-news.laohu8.com/highlight/detail?id=2665315217","media":"珠江时报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665315217?lang=zh_cn&edition=fundamental","pubTime":"2026-09-07 18:00","pubTimestamp":1788775200,"startTime":"0","endTime":"0","summary":"随着佛山市最低工资标准9月1日失业金自待遇所属期2026年9月起上调至2070元/月。（二）享受的待遇标准1、失业保险金：按我市企业职工最低工资标准的90%按月发放，待遇所属期2026年9月起是2070元/月。大龄领金人员达到法定退休年龄时，或出现停止领取失业保险金情形的，停止享受由失业保险基金继续承担企业职工基本养老保险费。2025年2月1日及之后申请失业保险金的失业人员，按修改后的省条例执行，不再发放求职补贴。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/wm/2026-09-07/doc-iniqyzxu6360828.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["XLV","BK4588","BK4585","XBI","LABU","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175448508","title":"医疗健康板块动态：市场快讯汇总","url":"https://stock-news.laohu8.com/highlight/detail?id=1175448508","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1175448508?lang=zh_cn&edition=fundamental","pubTime":"2026-09-07 16:23","pubTimestamp":1788769386,"startTime":"0","endTime":"0","summary":"0727 GMT——CGS国际分析师Kasem Prunratanamala在研报中指出，Klinique医疗诊所上调了2026年营收指引，但这一利好消息似乎已被市场提前消化。这家医疗美容诊所运营商将2026年营收目标从41.5亿泰铢上调至45亿泰铢，理由是7月份现金销售增长强劲。尽管公司运营势头稳健，同店销售增长韧性十足，但近期股价的强势表现已充分反映了大部分正面消息。该券商维持该股\"持有\"评级及28.00泰铢的目标价。目前股价报29.00泰铢，上涨1.75%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XLV","BK4588","BK4585","BK4581","LABU","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665954553","title":"人保健康保险大连分公司被罚27万，涉聘任不合格人员等","url":"https://stock-news.laohu8.com/highlight/detail?id=2665954553","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665954553?lang=zh_cn&edition=fundamental","pubTime":"2026-09-07 10:47","pubTimestamp":1788749245,"startTime":"0","endTime":"0","summary":"蓝鲸新闻9月7日讯，近日，国家金融监督管理总局大连监管局发布行政处罚决定书，剑指中国人民健康保险股份有限公司大连分公司及相关责任人。罚单显示，中国人民健康保险股份有限公司大连分公司的主要违法违规行为是：聘任不具有任职资格的人员；编制、提供虚假的报告报表文件资料。针对上述违法行为，国家金融监督管理总局大连监管局对中国人民健康保险股份有限公司大连分公司罚款27万元；对傅信弘警告，罚款7万元；对周笑俊警告，罚款7万元；对刘志东警告，罚款1万元；对李翔警告，罚款4万元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1788746879733984657","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK4585","XLV","LABU","BK4588","BK4581","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665500873","title":"阿斯利康(AZN.US)乳腺癌新药获FDA加速批准，华尔街预计2032年销售额有望冲刺23亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2665500873","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665500873?lang=zh_cn&edition=fundamental","pubTime":"2026-09-05 13:50","pubTimestamp":1788587400,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，阿斯利康的乳腺癌口服药已获得美国食品药品监督管理局的批准。阿斯利康曾表示，商品名为 Etcamah 的 camizestrant 最终有望带来超过 50 亿美元的年销售额。然而华尔街并未如此乐观：调查的分析师目前预计，该药在 2032 年的销售额近 23 亿美元。但在周五的批准声明中，该机构表示，这种药物将为乳腺癌女性患者提供一种额外的疾病治疗途径。该药适用于在接受内分泌疗法期间产生特定基因突变的乳腺癌患者。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1492433.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["FAZ","LABU","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665350082","title":"阿斯利康(AZN.US)乳腺癌新药获FDA加速批准，华尔街预计2032年销售额有望冲刺23亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2665350082","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665350082?lang=zh_cn&edition=fundamental","pubTime":"2026-09-05 13:50","pubTimestamp":1788587400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LABU","BK4585","FAZ","BK4588"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":8,"totalSize":200,"code":"91000000","status":"200"}]}}